Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.48 |
| ▸ | AHCY | P23526 | 2/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21139456 | 1.00 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL23080211 | 1.00 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL14075793 | 1.00 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL13966427 | 1.00 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL13975991 | 1.00 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL24600719 | 0.90 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL13400312 | 0.88 | PI4KA (0.53) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL13975989 | 0.88 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL13966423 | 0.88 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL20580185 | 0.87 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4273153-A1 | ADENOSINE A3 RECEPTOR AGONISTS, PREPARATION METHODS AND USES THEREOF | Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED | 2022-07-14 | — | — | US | disclosed |
| WO-2022143740-A1 | ADENOSINE A3 RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, AND USE THEREOF | 浙江春禾医药科技有限公司 | 2022-07-07 | — | — | WO | disclosed |
| US-11220524-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRELUDE THERAPEUTICS INCORPORATED (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210130388-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED | 2021-05-06 | — | — | US | disclosed |
| WO-2020206308-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2020-10-08 | — | — | WO | disclosed |
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10077284-B2 | UBA5 inhibitors | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2018-09-18 | — | — | US | disclosed |
| WO-2018152548-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2018-08-23 | — | — | WO | disclosed |
| US-20170107247-A1 | UBA5 INHIBITORS | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2017-04-20 | — | — | US | disclosed |
| EP-1239879-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | disclosed |
| EP-1239881-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001045714-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045682-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045685-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045683-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045715-A2 | COMBINATIONS OF AN ADENOSINE A1 AGONIST WITH AN OPIOID AND THEIR USE IN THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| WO-2001045686-A2 | FORMULATIONS OF ADENOSINE A1 AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-06-28 | — | — | WO | disclosed |
| EP-1090019-A1 | ADENOSINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067262-A1 | ADENOSINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428104-B2 | Substituted nucleoside derivatives useful as anticancer agents | TYMP, NME1, DPYD | PI4KA 769/4885PI4K2B 1095/4885PI4K2A 903/4885 |
| US-20210130388-A1 | SELECTIVE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | PI4KA 2213/4885PI4K2B 2369/4885PI4K2A 2854/4885 |
| US-10077284-B2 | UBA5 inhibitors | UBQLN2, UBTF, UBQLN1 | PI4KA 1575/4885PI4K2B 1568/4885PI4K2A 2218/4885 |
| US-20220218732-A1 | Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | PI4KA 2334/4885PI4K2B 2479/4885PI4K2A 3021/4885 |
| US-20170107247-A1 | UBA5 INHIBITORS | UBQLN2, UBTF, UBQLN1 | PI4KA 1575/4885PI4K2B 1568/4885PI4K2A 2218/4885 |
| US-11220524-B2 | Selective inhibitors of protein arginine methyltransferase 5 (PRMT5) | PRMT5, PRMT6, PRMT1 | PI4KA 2213/4885PI4K2B 2369/4885PI4K2A 2854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.